Targeting neuronal dysfunction and receptor imaging

Current Opinion in Biotechnology

Volumn 18, Issue 1, 2007, Pages 60-64

  Camacho, Valle ^a   Carrió, Ignasi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR SYSTEM; COMPUTERIZED TOMOGRAPHY; DISEASES; LIGHT EMISSION; MEDICAL IMAGING; TOXICITY;

CARDIAC NEUROTRANSMISSION; ISCHEMIC HEART DISEASES; METAIODOBENZYLGUANIDINE; PHYSIOPATHOLOGY;

NEUROLOGY;

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DOXORUBICIN; GUANETHIDINE; IODINE 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NEUROTRANSMITTER; NORADRENALIN; POTASSIUM PERCHLORATE; PROTEIN S 100;

ADRENERGIC SYSTEM; AUTONOMIC NEUROPATHY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DYSAUTONOMIA; GENETIC PREDISPOSITION; HEART DISEASE; HEART FAILURE; HEART INNERVATION; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR IMAGING; NERVE CELL LESION; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECOND MESSENGER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; DIAGNOSTIC IMAGING; HEART; HEART DISEASES; HUMANS; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33846861520     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.01.002     Document Type: Review

References (35)

1. Carrió I. Cardiac neurotransmission imaging. J Nucl Med 42 (2001) 1062-1076
2. 123I-MIBG studies in various forms of cardiac disease.
3. 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J Nucl Med 40 (1999) 1-5
4. Paul M., Schäfers M., Kies P., Acil T., Schäfers K., Breithardt G., Schober O., and Witchter T. Impact of sympathetic innervation on recurrent life-threating arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 33 (2006) 866-870
5. 123I-MIBG scintigraphy, measurements of heart rate variability and immunohistochemical studies of endomyocardial biopsy specimens with anti-S100 antibodies.
6. 123I-MIBG imaging. J Nucl Med 40 (1999) 911-916
7. Lovric S.S., Avbelj V., Trobec R., Zorman D., Rakovec P., Hojker S., Gersak B., and Milcinski M. Sympathetic reinnervation after heart transplantation assessed by iodine-123 metaiodobenzylguanidine imaging, and heart variability. Eur J Cardiothorac Surg 26 (2004) 736-741
8. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 189-194
9. Druschky A., Hilz M.J., Platsch G., Radespiel-Troger M., Druschky K., Kuwert T., and Neundorfer B. Differentiation of Parkinson's disease and multiple system atrophy in early stages by means of I-123-MIBG-SPECT. J Neurol Sci 175 (2000) 3-12
10. Kashihara K., and Yamamoto M. Myocardial (123)I-MIBG scintigraphy in patients with PSP, CBD and MSA. J Neurol 253 suppl 3 (2006) iii35-iii40
11. 123I-MIBG scintigraphy might improve sensitivity in the detection of dementia with Lewy bodies, and could constitute a potential tool to discriminate dementia with Lewy bodies from Alzheimer's disease, especially when it is difficult to distinguish these diseases using brain perfusion SPECT.
12. 123I-MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 71 (2001) 583-588
13. Orimo S., Amino T., Takahashi A., Kojo T., Uchihara T., Mori F., Wakabayashi K., and Takahashi H. Cardiac sympathetic denervation in Lewy body disease. Parkinsonism Relat Disord 12 (2006) S99-S105
14. Patel A., and Iskandrian A. MIBG imaging. J Nucl Cardiol 9 (2002) 75-94
15. Matsunari I., Schricke U., Bengel F.M., Haase H.U., Barthel P., Schmidt G., Nekolla, Schoeming A., and Schwaiger M. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 101 (2000) 2579-2585
16. Simula S., Lakka T., Kuikka J., Laitinen T., Remes J., Kettunen R., and Hartikainen J. Cardiac adrenergic innervation within the first 3 months after acute myocardial infarction. Clin Physiol 20 (2000) 366-373
17. Simula S., Vanninen E., Viitanen L., Kareinen A., Letho S., Pajunen P., Syvanne M., Kuikka J., Laakso M., and Hartikainen J. Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary artery disease. J Nucl Med 43 (2002) 1-7
18. Maron B.J., Olivotto I., Spirito P., Casey S.A., Bellone P., Gohman T.E., Graham K.J., Burton D.A., and Cecchi F. Epidemiology of hypertrophic cardiomiopathy -related death: revisited in a large non-referal-based patient population. Circulation 102 (2000) 858-864
19. Marian A.J., and Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiolol 33 (2001) 655-670
20. Sipola P., Vanninen E., Aronen H.J., Lauerma K., Simula S., Jaakelaien P., Laakso M., Peuhkurinen K., Kuusisto J., and Kuikka J.T. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogeneous subjects with hypertrophic cardiomyopathy. J Nucl Med 44 (2003) 1612-1617
21. Shimizu M., Ino H., Yamaguchi M., Terai H., Hayashi K., Nakajima K., Taki J., and Mabuchi H. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med 43 (2002) 15-20
22. 123I-MIBG: relationship with left ventricular perfusion and function. Q J Nucl Med Mol Imaging 48 (2004) 20-25
23. 123I-MIBG scintigraphy could allow detection of patients with impaired LV functional reserve.
24. Parthenakis F.I., Prassopoulos V.K., Koukouraki S.I., Zacharis E.A., Diakakis G.F., Karkavitsas N.K., and Vardas P.E. Segmental pattern of myocardial sympathetic denercation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and perfusion abnormalities. J Nucl Cardiol 9 (2002) 15-22
25. Merlet P., Benvenuti C., Moyse D., Pouillart F., Dubois-Rande J.L., Duval A.M., Loisance D., Castaigne A., and Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40 (1999) 917-923
26. 123I-metaiodobenzilguanidine uptake. J Nucl Med 42 (2001) 49-54
27. 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 31 (2004) 1356-1361
28. 123I-MIBG scintigraphy and left ventricular ejection fraction for predicting cardiac events in patients with dilated cardiomyopathy stabilized by beta-blocker treatment.
29. Jeon T.J., Lee J.D., Ha J.W., Yang W.I., and Cho S.H. Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. Eur J Nucl Med 27 (2000) 686-693
30. Nousiainen T., Vanninen E., Jantunen E., Remes J., Kuikka J., and Hartikainen J. Anthracicline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol 21 (2001) 123-128
31. 123I-MIBG. Diabetes Nutr Metab 13 (2000) 350-355
32. 123I-MIBG scintigraphy is a useful non-invasive technique for predicting cardiac events and long-term mortality in non-insulin-dependent diabetes mellitus patients, and for selecting patients who are at risk of neuronal damage and who might benefit from cardioprotector treatment.
33. Sugiyama T., Murata C., Tawarahara K., and Nakano T. Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus?. J Nucl Cardiol 7 (2000) 562-568
34. 123I-MIBG. J Nucl Med 40 (1999) 6-11
35. 123I-metaiodobenzylguanidine left ventricular imaging. J Nucl Med 41 (2000) 1127-1133